logo-loader
viewSativa Group PLC

Sativa capitalises on first-mover advantage in UK medicinal cannabis

Snapshot

  • UK’s first medicinal cannabis investment vehicle
  • Now operates with two fully trading UK businesses
  • Commercial deals clinched with suppliers of cannabis oil
  • Sativa to roll out CBD wellness retail centres and clinics
Sativa

Quick facts: Sativa Group PLC

Price: 4.75 GBX

NEX:SATI
Market: NEX
Market Cap: -
Follow

What Sativa does

Sativa Group PLC (NEX:SATI) is Britain's first medicinal cannabis investment vehicle and is now an operating company with two fully trading UK businesses.

Listed on the NEX exchange in March 2018, Sativa was set up to make investments into Canada-based cannabis companies where the drug is now approved for medicinal and recreational use. 

Since the legalisation of medicinal cannabis in the UK in late 2018, Sativa has capitalised on its first-mover advantage to become a seed-to-consumer medicinal cannabis and cannabidiol (CBD) wellness business. 

It is now focused on the sourcing of raw material, advanced extraction, manufacture, testing, distribution, and research & development of cannabis products.

In October 2019, the company received a controlled drug licence from the UK Home Office, allowing it to produce and supply cannabis at its headquarters in Somerset.

The medicinal cannabis firm said it will immediately begin a research partnership agreement with King’s College London to research the impact of cannabinoids on inflammation and respiratory conditions.

 

What Sativa owns

Sativa’s investments include: Canada-based pharmaceutical firm, Veritas Pharma.; Canada pharma-tech business, Rapid Dose Therapeutics, which owns the QuickStrip oral dissolving cannabis strips; and a 60% stake in a joint venture with Germany's Lexamed GmbH.

Its two operating subsidiaries are testing facility, PhytoVista Laboratories, and George Botanicals, which develops, manufactures and distributes low-Tetrahydrocannabinol (THC) and CBD wellness products.

In 2019 it launched brands Goodbody Botanicals and Goodbody Wellness, tapping into the health and beauty industries.

 

How it is doing

Gross profits and underlying earnings (EBITDA) for the year to 31 December to be ahead of guidance, while revenue is set to come in more than five times higher than 2018.

It concluded 2019 with a £1.38mln share placing to fund the next stage of its development as it aims to ramp up sales in 2020.

 

 

What the CEO says: Henry Lees-Buckley

"2019 was a year of progress for Sativa, with the focus being on building a strong foundation for growth."  

"I am confident 2020 will be a breakout year and will solidify our position as a leading UK CBD wellness and medicinal cannabis company."

 

Video

 

 

Inflexion points

  • In November, Sativa said that it was exploring a potential listing on AIM in 2020
  • The company has appointed Clive Page, professor of pharmacology at King's College London, to its medical advisory board
  • Sativa has signed commercial offtake agreements with two suppliers of cannabis oil for the manufacture of CBD products in the UK. These suppliers are Swiss firm, Alponics, and Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Sativa Group PLC named herein, including the promotion by the Company of Sativa Group PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Sativa Investments PLC acquires UK-based PhytoVista Laboratories

Geremy Thomas, chief executive of Sativa Investments PLC (NEX:SATI), tells Proactive's Andrew Scott they've agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000. The British medicinal cannabis investment vehicle will pay £235,000...

on 4/7/18

3 min read